NASDAQ:LTRN

Lantern Pharma Q2 2025 Earnings Results & Report

Lantern Pharma logo
$0.24 -0.04 (-13.70%)
Closing price 11/20/2026 03:56 PM Eastern
Extended Trading
$0.25 +0.00 (+0.41%)
As of 11/20/2026 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lantern Pharma beat analyst earnings expectations in its Q2 2025 results, released August 13, 2025. The company reported EPS of -$0.40 versus the -$0.53 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

Lantern Pharma EPS Results

Actual EPS
-$0.40
Consensus EPS
-$0.53
Beat/Miss
Beat by +$0.13
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Lantern Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Lantern Pharma Q2 2025 Earnings FAQ

Lantern Pharma (NASDAQ:LTRN) reported earnings of -$0.40 per share for Q2 2025, beating the consensus estimate of -$0.53. The report was announced on Wednesday, August 13, 2025.

Lantern Pharma Earnings Headlines

Lantern Pharma (NASDAQ: LTRN) CEO resigns and cash falls to $7.6 million
Lantern Pharma (NASDAQ:LTRN) Stock Gets Downgrade from Rodman & Renshaw
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
Lantern Pharma Reports Delay in Quarterly Filing
Lantern Pharma (LTRN) Set to Announce Quarterly Earnings on Wednesday
See More Lantern Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lantern Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lantern Pharma and other key companies, straight to your email.

About Lantern Pharma

Lantern Pharma (NASDAQ:LTRN) is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. It uses its artificial intelligence and machine-learning platform, RADR, to analyze cancer data and help identify drug candidates, potential biomarkers and patient groups that may respond to treatment.

The company’s development pipeline includes investigational therapies for several cancers. Its candidates include LP-300, being studied for certain patients with non-small cell lung cancer, and LP-184 and LP-284, which are being developed for selected solid tumors and blood cancers. These therapies are investigational and are not approved medicines.

Lantern Pharma is headquartered in Dallas, Texas. Panna Sharma serves as the company’s chief executive officer and is a co-founder.

View Lantern Pharma Profile